📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. (2020)

First Author: Tallantyre EC

Attributed to: MRC Centre for Neuropsychiatric Genetics and Genomics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.msard.2020.102056

PubMed Identifier: 32353753

Publication URI: http://europepmc.org/abstract/MED/32353753

Type: Journal Article/Review

Volume: 42

Parent Publication: Multiple sclerosis and related disorders

ISSN: 2211-0348